DERIVADOS DE CAMPTOTECINA ALTAMENTE LIPOFILOS

Compuesto que tiene la fórmula general (1): en la que: R1 es -X-(alquilen C1-C6)-SiR8R9R10; R2 es halo, alquilo C1-C6, amino o nitro; R8, R9 y R10 son cada uno individualmente alquilo C1-C6; R11 es hidrógeno, hidroxilo o acetoxilo; y X es azufre o X no está presente; o una sal farmacéuticamente acep...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	REDDY, DASHARATHA, G, HAUSHEER, FREDERICK, H, HARIDAS, KOCHAT, YAO, SHIJIE, PETLURU, PAVANKUMAR, N., V, SEETHARAMULU, P
Format:	Patent
Sprache:	spa
Schlagworte:	ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM AGRICULTURE ANIMAL HUSBANDRY BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES, AS HERBICIDES CHEMISTRY FISHING FORESTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HUNTING HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEST REPELLANTS OR ATTRACTANTS PLANT GROWTH REGULATORS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTSTHEREOF SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS TRAPPING
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Compuesto que tiene la fórmula general (1): en la que: R1 es -X-(alquilen C1-C6)-SiR8R9R10; R2 es halo, alquilo C1-C6, amino o nitro; R8, R9 y R10 son cada uno individualmente alquilo C1-C6; R11 es hidrógeno, hidroxilo o acetoxilo; y X es azufre o X no está presente; o una sal farmacéuticamente aceptable del mismo. This invention relates to novel derivatives of camptothecin, and will, particularly to derivatives having a substitution at the C-7 position, or at one of the C-9, C-10, C-11 or C-12 positions, or to disubstituted derivatives having a first substitution at C-7 and a second at one of C-9, C-10, C-11 or C-12. The invention also includes methods of using the compounds as Topoisomerase I inhibitors to treat patients with cancer. The invention also includes pharmaceutical formulations which consist of the novel compounds in solution or suspension with one or more pharmaceutical excipients or diluents.